{
  "doc_id": "01_Article_Iptacopan C3G Trial",
  "doc_filename": "01_Article_Iptacopan C3G Trial.pdf",
  "trial_ids": [
    {
      "id_type": "NCT",
      "value": "NCT04817618",
      "registry": "ClinicalTrials.gov",
      "url": "https://clinicaltrials.gov/study/NCT04817618",
      "title": null
    }
  ],
  "study_design": {
    "phase": "3",
    "design_type": "parallel",
    "blinding": "double-blind",
    "randomization_ratio": null,
    "allocation": "iptacopan n=38, placebo n=36",
    "sample_size": null,
    "actual_enrollment": 74,
    "duration_months": 12,
    "treatment_arms": [
      {
        "name": "Iptacopan",
        "n": 38,
        "dose": "200mg",
        "frequency": "twice daily",
        "route": "oral"
      },
      {
        "name": "Placebo",
        "n": 36,
        "dose": null,
        "frequency": "twice daily",
        "route": "oral"
      }
    ],
    "control_type": "placebo",
    "setting": "35 hospitals or medical centres across 18 countries",
    "sites_total": 35,
    "countries_total": 18,
    "periods": [
      {
        "name": "double_blind",
        "duration_months": 6.0,
        "duration_weeks": null,
        "description": null
      },
      {
        "name": "open_label",
        "duration_months": 6.0,
        "duration_weeks": null,
        "description": null
      }
    ],
    "evidence": [
      {
        "page": 3,
        "section_header": null,
        "quote": "APPEAR-C3G was a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study of ptacopan versus placebo",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "01_Article_Iptacopan C3G Trial"
      },
      {
        "page": 3,
        "section_header": null,
        "quote": "the study was conducted in 35 hospitals or medical centres across 18 countries",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "01_Article_Iptacopan C3G Trial"
      },
      {
        "page": 4,
        "section_header": null,
        "quote": "Iptacopan 200 mg (n=38) Placebo (n=36)",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "01_Article_Iptacopan C3G Trial"
      },
      {
        "page": 5,
        "section_header": null,
        "quote": "participants took 200 mg iptacopan orally (formulated as a 200 mg capsule) twice daily (morning and evening) for 6 months (double-blind) followed by open-label iptacopan at 200 mg twice daily for an additional 6 months",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "01_Article_Iptacopan C3G Trial"
      },
      {
        "page": 5,
        "section_header": null,
        "quote": "participants took placebo orally (formulated as a 200 mg matching capsule) twice daily for 6 months double-blind) followed by open-label iptacopan 200 mg twice daily orally for an additional 6 months",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "01_Article_Iptacopan C3G Trial"
      }
    ]
  },
  "eligibility_inclusion": [
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "Adult participants (aged between 18 years and 60 years)",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "inclusion",
        "category": "age",
        "derived": {
          "operator": "range",
          "value": "18-60",
          "unit": "years"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "Adult participants (aged between 18 years and 60 years)",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "biopsy-confirmed C3 glomerulopathy within 12 months of enrolment as assessed by the investigator and local histopathologist",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "inclusion",
        "category": "diagnosis",
        "derived": {
          "operator": "<=",
          "value": 12,
          "unit": "months"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "biopsy-confirmed C3 glomerulopathy within 12 months of enrolment as assessed by the investigator and local histopathologist",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "reduced serum C3 concentration (ie, <77 mg/dL [defined as <0-85xlower limit of the central laboratory normal range]) at screening",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "inclusion",
        "category": "biomarker",
        "derived": {
          "operator": "<",
          "value": 77,
          "unit": "mg/dL"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "reduced serum C3 concentration (ie, <77 mg/dL [defined as <0-85xlower limit of the central laboratory normal range]) at screening",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "urine protein—creatinine ratio (UPCR) of 1-0 g/g or higher (first morning void urine sample) at day -75 and day -15 before randomisation",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "inclusion",
        "category": "lab_value",
        "derived": {
          "operator": ">=",
          "value": 1.0,
          "unit": "g/g"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "urine protein—creatinine ratio (UPCR) of 1-0 g/g or higher (first morning void urine sample) at day -75 and day -15 before randomisation",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "eGFR of 30 mL/min per 1-73 m? or higher at screening and day —15 before randomisation",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "inclusion",
        "category": "organ_function",
        "derived": {
          "operator": ">=",
          "value": 30,
          "unit": "mL/min per 1.73 m²"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "eGFR of 30 mL/min per 1-73 m? or higher at screening and day —15 before randomisation",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "Vaccination against Neisseria meningitidis and Streptococcus pneumoniae before study entry or during the screening period was mandatory",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "inclusion",
        "category": "prior_treatment",
        "derived": {
          "operator": "boolean"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "Vaccination against Neisseria meningitidis and Streptococcus pneumoniae before study entry or during the screening period was mandatory",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_INCLUSION",
      "text": "all participants received maximally tolerated doses of angiotensin-converting enzyme inhibitors or AT1-receptor blockers for at least 90 days",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "inclusion",
        "category": "prior_treatment",
        "derived": {
          "operator": ">=",
          "value": 90,
          "unit": "days"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "all participants received maximally tolerated doses of angiotensin-converting enzyme inhibitors or AT1-receptor blockers for at least 90 days",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    }
  ],
  "eligibility_exclusion": [
    {
      "field_type": "ELIGIBILITY_EXCLUSION",
      "text": "receipt of any cell or solid organ transplantation",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "exclusion",
        "category": "prior_treatment",
        "derived": {
          "operator": "boolean"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "receipt of any cell or solid organ transplantation",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_EXCLUSION",
      "text": "rapidly progressive crescentic glomerulonephritis",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "exclusion",
        "category": "diagnosis",
        "derived": {
          "operator": "boolean"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "rapidly progressive crescentic glomerulonephritis",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_EXCLUSION",
      "text": "kidney biopsy showing interstitial fibrosis or tubular atrophy",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "exclusion",
        "category": "diagnosis",
        "derived": {
          "operator": "boolean"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "kidney biopsy showing interstitial fibrosis or tubular atrophy",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "ELIGIBILITY_EXCLUSION",
      "text": "monoclonal gammopathy of undetermined significance",
      "section": "eligibility",
      "page": 3,
      "structured_data": {
        "type": "exclusion",
        "category": "comorbidity",
        "derived": {
          "operator": "boolean"
        }
      },
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "quote": "monoclonal gammopathy of undetermined significance",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    }
  ],
  "epidemiology": [],
  "patient_journey": [],
  "endpoints": [
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Proteinuria reduction",
      "section": "endpoints",
      "page": 5,
      "structured_data": {
        "type": "primary",
        "name": "Proteinuria reduction",
        "measure": "24-hour UPCR",
        "timepoint": "6 months",
        "analysis_method": "log-transformed ratio to baseline"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 5,
          "quote": "the primary endpoint was relative reduction in proteinuria (as measured by log- transformed ratio to baseline in UPCR sampled from a 24-h urine collection) between groups at 6 months",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "eGFR change",
      "section": "endpoints",
      "page": 5,
      "structured_data": {
        "type": "secondary",
        "name": "eGFR change",
        "measure": "eGFR change from baseline",
        "timepoint": "6 months",
        "analysis_method": null
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 5,
          "quote": "difference in eGFR (change from baseline at 6 months",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Composite renal endpoint",
      "section": "endpoints",
      "page": 5,
      "structured_data": {
        "type": "secondary",
        "name": "Composite renal endpoint",
        "measure": "Proportion achieving stable/improved eGFR and proteinuria reduction",
        "timepoint": "6 months",
        "analysis_method": null
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 5,
          "quote": "proportion of participants who achieved a composite renal endpoint (stable or improved eGFR [<15% reduction compared with the baseline visit and =>50% reduction in UPCR from baseline to 6 months)",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Glomerular inflammation reduction",
      "section": "endpoints",
      "page": 5,
      "structured_data": {
        "type": "secondary",
        "name": "Glomerular inflammation reduction",
        "measure": "Disease total activity score in renal biopsy",
        "timepoint": "6 months",
        "analysis_method": "change from baseline"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 5,
          "quote": "effect of iptacopan versus placebo in reducing glomerular inflammation in the kidney (change from baseline in disease total activity score in a renal biopsy at 6 months)",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Patient-reported fatigue",
      "section": "endpoints",
      "page": 5,
      "structured_data": {
        "type": "secondary",
        "name": "Patient-reported fatigue",
        "measure": "FACIT-Fatigue score",
        "timepoint": "6 months",
        "analysis_method": "change from baseline"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 5,
          "quote": "patient-reported fatigue (change from baseline to 6 months in the FACIT-Fatigue score)",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Adverse events",
      "section": "endpoints",
      "page": 5,
      "structured_data": {
        "type": "safety",
        "name": "Adverse events",
        "measure": "Any untoward medical occurrence",
        "timepoint": "6-month double-blind period",
        "analysis_method": null
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 5,
          "quote": "to evaluate the safety profile and tolerability of iptacopan compared with placebo during the 6-month double-blind period. An adverse event was defined as any untoward medical occurrence (eg, any unfavourable and unintended sign, symptom, or disease)",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Serum C3 change",
      "section": "endpoints",
      "page": 5,
      "structured_data": {
        "type": "exploratory",
        "name": "Serum C3 change",
        "measure": "Serum C3",
        "timepoint": "6 months",
        "analysis_method": "log-transformed ratio to baseline"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 5,
          "quote": "evaluate the change in serum C3 with iptacopan compared with placebo (log-transformed ratio to baseline in serum C3 at 6 months)",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Glomerular C3 deposition",
      "section": "endpoints",
      "page": 5,
      "structured_data": {
        "type": "exploratory",
        "name": "Glomerular C3 deposition",
        "measure": "Glomerular C3 deposit and total chronicity scores from renal biopsy",
        "timepoint": "6 months",
        "analysis_method": "change from baseline"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 5,
          "quote": "evaluate the effect of iptacopan compared with placebo on glomerular C3 deposition (change from baseline in glomerular C3 deposit and total chronicity scores from a renal biopsy at 6 months)",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    {
      "field_type": "STUDY_ENDPOINT",
      "text": "Complement biomarkers",
      "section": "endpoints",
      "page": 5,
      "structured_data": {
        "type": "exploratory",
        "name": "Complement biomarkers",
        "measure": "Plasma and urinary complement biomarkers",
        "timepoint": null,
        "analysis_method": "change from baseline"
      },
      "confidence": 0.88,
      "evidence": [
        {
          "page": 5,
          "quote": "the effect of iptacopan versus placebo on plasma and urinary complement biomarkers (change from",
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    }
  ],
  "sites": [],
  "operational_burden": {
    "invasive_procedures": [
      {
        "name": "renal biopsy",
        "timing": [
          "within 12 months of enrollment"
        ],
        "timing_days": [
          -365
        ],
        "optional": false,
        "purpose": "diagnosis_confirmation",
        "is_eligibility_requirement": true,
        "evidence": [
          {
            "page": 3,
            "section_header": null,
            "quote": "Adult participants (aged between 18 years and 60 years) with biopsy-confirmed C3 glomerulopathy within 12 months of enrolment as assessed by the investigator and local histopathologist were enrolled into the study",
            "char_start": null,
            "char_end": null,
            "bbox": null,
            "source_node_id": null,
            "source_doc_id": "01_Article_Iptacopan C3G Trial"
          }
        ]
      }
    ],
    "visit_schedule": {
      "total_visits": null,
      "visit_days": [],
      "frequency": null,
      "duration_weeks": 26,
      "scheduled_visits": [],
      "pre_randomization_days": [],
      "on_treatment_days": [],
      "follow_up_days": [],
      "evidence": []
    },
    "central_lab_required": true,
    "central_lab": {
      "required": true,
      "analytes": [
        "C3"
      ],
      "confidence": 0.85,
      "evidence": [
        {
          "page": 3,
          "section_header": null,
          "quote": "reduced serum C3 concentration (ie, <77 mg/dL [defined as <0-85xlower limit of the central laboratory normal range])",
          "char_start": null,
          "char_end": null,
          "bbox": null,
          "source_node_id": null,
          "source_doc_id": "01_Article_Iptacopan C3G Trial"
        }
      ]
    },
    "special_sample_handling": [
      "first morning void",
      "24-h urine collection"
    ],
    "vaccination_requirements": [
      {
        "vaccine_type": "meningococcal",
        "requirement_type": "required",
        "timing": "before study entry or during the screening period",
        "agents": [],
        "evidence": [
          {
            "page": 3,
            "section_header": null,
            "quote": "Vaccination against Neisseria meningitidis and Streptococcus pneumoniae before study entry or during the screening period was mandatory",
            "char_start": null,
            "char_end": null,
            "bbox": null,
            "source_node_id": null,
            "source_doc_id": "01_Article_Iptacopan C3G Trial"
          }
        ]
      },
      {
        "vaccine_type": "pneumococcal",
        "requirement_type": "required",
        "timing": "before study entry or during the screening period",
        "agents": [],
        "evidence": [
          {
            "page": 3,
            "section_header": null,
            "quote": "Vaccination against Neisseria meningitidis and Streptococcus pneumoniae before study entry or during the screening period was mandatory",
            "char_start": null,
            "char_end": null,
            "bbox": null,
            "source_node_id": null,
            "source_doc_id": "01_Article_Iptacopan C3G Trial"
          }
        ]
      }
    ],
    "background_therapy": [
      {
        "therapy_class": "ACE inhibitor/ARB",
        "requirement_type": "required",
        "requirement": "maximally tolerated doses for at least 90 days",
        "agents": [
          "angiotensin-converting enzyme inhibitors",
          "AT1-receptor blockers"
        ],
        "stable_duration_days": 90,
        "max_dose": null,
        "evidence": [
          {
            "page": 3,
            "section_header": null,
            "quote": "Before randomisation, all participants received maximally tolerated doses of angiotensin-converting enzyme inhibitors or AT1-receptor blockers for at least 90 days",
            "char_start": null,
            "char_end": null,
            "bbox": null,
            "source_node_id": null,
            "source_doc_id": "01_Article_Iptacopan C3G Trial"
          }
        ]
      }
    ],
    "concomitant_meds_allowed": [],
    "run_in_duration_days": null,
    "run_in_requirements": [],
    "burden_score": null,
    "site_complexity_score": null,
    "hard_gates": [
      "biopsy requirement",
      "vaccination",
      "central lab C3 threshold"
    ]
  },
  "screening_flow": {
    "planned_sample_size": null,
    "actual_enrollment": 74,
    "screened": 132,
    "screen_failures": 58,
    "randomized": 74,
    "treated": 74,
    "completed": 73,
    "discontinued": 1,
    "screening_yield": 0.5606,
    "screen_failure_rate": 43.94,
    "dropout_rate": 0.0135,
    "screen_failure_rate_reported": 44.0,
    "screen_failure_rate_computed": 43.94,
    "screen_fail_reasons": [],
    "reasons_can_overlap": false,
    "run_in_failures": null,
    "run_in_failure_reasons": [],
    "evidence": [
      {
        "page": 6,
        "section_header": null,
        "quote": "Between July 28, 2021, and Feb 15, 2023, 132 participants were screened, of whom 58 (44%) did not complete the screening and run-in period and 74 (56%) were randomised 1:1 to receive either iptacopan (n=38) or placebo (n=36; figure 1).",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "01_Article_Iptacopan C3G Trial"
      },
      {
        "page": 6,
        "section_header": null,
        "quote": "All 74 participants randomly assigned to treatment groups completed the 6-month double-blind period (appendix p 18); 73 participants completed the 12-month study (double-blind and open-label period).",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "01_Article_Iptacopan C3G Trial"
      },
      {
        "page": 6,
        "section_header": null,
        "quote": "One participant in the placebo group discontinued treatment during the open-label period as per participant decision and was lost to follow-up.",
        "char_start": null,
        "char_end": null,
        "bbox": null,
        "source_node_id": null,
        "source_doc_id": "01_Article_Iptacopan C3G Trial"
      }
    ]
  },
  "extraction_timestamp": "2026-02-04T13:36:06.611225"
}